The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular condition. It is the leading cause of sudden ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

Aficamten is a small molecule cardiac myosin inhibitor designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle.

PDUFA Target Action Date Set for September 26, 2025SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted the company’s New ...

Favorable short- and long-term outcomes are seen in patients with hypertrophic cardiomyopathy who receive septal reduction therapy.

Background Fabry disease (FD) causes multiorgan sphingolipid accumulation, with cardiac involvement responsible for the ...

This group of pathological conditions includes dilated cardiomyopathy, hypertrophic cardiomyopathy ... occurs even in the absence of observable clinical features of cardiomyopathy.

Describes the nature of a clinical study. Types include ... LV end-diastolic wall thickness that meets a threshold of: Z-score > 2.5 in the absence of symptoms or family history or Z-score > 2 in the ...

Cytokinetics, Bayer enter collaboration and licensing pact to develop & commercialize aficamten in Japan: South San Francisco, California Wednesday, November 20, 2024, 15:00 Hrs [ ...